skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Immunoconjugate RO5479599 (Code C104058)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Immunoconjugate RO5479599

Definition: An immunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3), with potential antineoplastic activity. Upon administration, RO5479599 binds to the extracellular domain of HER3 and inhibits HER3 dimerization; thereby, preventing EGFR-dependent signaling. In addition, RO5479599 stimulates the immune system to exert antibody-dependent cellular cytotoxicity (ADCC). This may decrease proliferation of HER3-overexpressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.

Label: Immunoconjugate RO5479599

NCI Thesaurus Code: C104058 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL433954  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Immunoconjugate RO5479599

External Source Codes: 
PDQ Closed Trial Search ID 744816
PDQ Open Trial Search ID 744816 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C104058
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom